08/23/2012
Reported online last week in Science Translational Medicine, researchers at MIT and Harvard used nanoparticles to demonstrate the nanoparticles that target a protein called ID4 can reduce ovarian cancer tumors in mice.
Researchers hope that this approach could help speed the development of new drugs. As new technology allows researchers to sequence cancer cell genomes, researchers are finding more and more gene mutations and deletions that may be therapeutic targets. This approach—using a mouse model to determine which ones are important—may help researchers prioritize which ones to focus drug development efforts on.
Click here for the abstract.
Related Topics
OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued
OCRA-Funded Research Expands Impact of DNA and RNA Data
A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued